Tirzepatide vs Retatrutide

These two get compared constantly, and for good reason: they're the two compounds people ask about most in the weight-management space right now. The core difference is straightforward — how many receptors each one targets.

The mechanical difference

Tirzepatide — dual agonist (GLP-1 + GIP)

Tirzepatide activates two receptors: GLP-1 and GIP. It's the active compound in Mounjaro and Zepbound, and it's FDA-approved — that's a meaningful distinction, because it means it went through full clinical trials for safety and efficacy.

Retatrutide — triple agonist (GLP-1 + GIP + glucagon)

Retatrutide adds a third target: the glucagon receptor. The theory is that glucagon receptor activation increases energy expenditure, adding a mechanism on top of the appetite and insulin effects.

Critically, retatrutide is still investigational. It is not FDA-approved. It's in clinical trials.

What the trial data suggests

Published trial results for retatrutide have shown notable weight reduction figures, which is why it generates so much attention. Tirzepatide's trial results are also strong and, importantly, are backed by a longer track record and post-approval real-world data.

Here's the honest framing: comparing headline percentages across different trials, with different populations, durations, and dosing schedules, is not a clean comparison. It's a common mistake in online discussion. A larger number from a shorter trial in a different population doesn't straightforwardly mean "better."

Side effects

Both are GLP-1-based and share the familiar profile: nausea, vomiting, diarrhea, constipation, and appetite suppression — typically worst during dose escalation and often easing with time.

Retatrutide's glucagon component has been associated with increased heart rate in trial data, which is one of the things still being characterized. This is precisely the kind of thing that longer-term data exists to answer, and one of the reasons the approval distinction matters.

Dosing structure

Both use a gradual titration approach — starting low and increasing over weeks. This isn't optional or a suggestion; escalating too fast is the most common reason people have a miserable time and quit.

• Tirzepatide: commonly starts at 2.5 mg weekly, increasing every 4 weeks
• Retatrutide: trial protocols also used gradual escalation over months

Which one do people choose?

Being straightforward: that's a decision for you and a physician, not an article. What's worth understanding is the tradeoff. Tirzepatide offers an approved compound with a known safety profile and a long track record. Retatrutide is a newer mechanism with promising early data and, by definition, less known about long-term effects.

Neither of those is a small consideration when you're talking about a compound you'd take weekly for a year or more.

The bottom line

Tirzepatide targets two receptors and is FDA-approved. Retatrutide targets three and is still investigational. Both require slow titration. The mechanism difference is interesting; the approval difference is the one that should actually inform your decision-making.

Frequently asked questions

What's the difference between tirzepatide and retatrutide?

Tirzepatide is a dual agonist targeting GLP-1 and GIP receptors, and is FDA-approved (Mounjaro/Zepbound). Retatrutide is a triple agonist that adds glucagon receptor activation, and is still investigational — not FDA-approved.

Is retatrutide stronger than tirzepatide?

Trial data for retatrutide has shown notable weight reduction, but comparing figures across separate trials with different populations and durations isn't a clean comparison. Retatrutide also lacks the long-term safety data that comes with approval.

Is retatrutide FDA approved?

No. Retatrutide is investigational and remains in clinical trials. Tirzepatide is FDA-approved.

What is a triple agonist?

A triple agonist activates three receptors. Retatrutide targets GLP-1, GIP, and glucagon receptors — the glucagon component is theorized to increase energy expenditure, adding a mechanism beyond appetite and insulin effects.

Do tirzepatide and retatrutide have the same side effects?

They share the typical GLP-1 profile: nausea, vomiting, diarrhea, constipation, and appetite suppression, usually worst during dose escalation. Retatrutide's glucagon component has additionally been associated with increased heart rate in trial data.

For educational and research purposes only. Not medical advice. Consult a physician before starting any peptide protocol. BioHack is a tracking tool and does not sell peptides.